Navigation Links
Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
Date:9/25/2008

c disorders to the Company, but also a strong background in strategy, medical affairs and management."

The Senior Vice President and Head of Obesity and Metabolic Disorders is a new position at Orexigen. Dr. Kim will report to Eduardo Dunayevich, M.D., Chief Medical Officer.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... 2014 Cereal grain scientists, quality ... gather October 5–8, 2014, for the AACC International ... Center in Providence, Rhode Island. The comprehensive scientific ... food scientists, chemists, microbiologists, nutritionists, and those interested ... management. To date, 1,000 attendees have registered for ...
(Date:9/18/2014)... USA (PRWEB) September 18, 2014 Bipartisan ... of a bill designed to stimulate development and commercialization ... is being praised by leaders of SPIE, the ... the Revitalizing American Manufacturing and Innovation (RAMI) Act, now ... bill’s authors have said they are optimistic that it ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3
... ... EDMONTON, May 9 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),a ... update on its pipeline products, HYC750 and development with,BioCyDex Inc., ... Bio. Inc. for HYC750, a technology based on hyaluronic acid that,has ...
... May 9 The Alexander von Humboldt,Foundation, one of ... has named Dr. Robert Knight as a winner of ... area of neurobiology.,It is the only prize that the ... Germany, the Humboldt Foundation reviews a,select group of international ...
... 9 ATS Medical, Inc. (Nasdaq:,ATSI), manufacturer and ... it will participate at the Rodman & Renshaw,5th ... Beach Plaza,Hotel in Monte Carlo on Tuesday, May ... Medical, will present at 9:20 a.m. local time., ...
Cached Biology Technology:BioMS Medical Provides Update On Pipeline Products 2BioMS Medical Provides Update On Pipeline Products 3NeuroFocus Chief Science Advisor Wins Humboldt Prize 2ATS Medical to Participate at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:9/18/2014)... ANTONIO, September 18, 2014 New research into the ... causes a severe hemorrhagic disease in humans similar to ... essential for CCHFV infection. This discovery has the potential ... the pathogen. , The research, reported in ... Pathogens and conducted by scientists at the Texas ...
(Date:9/18/2014)... prompts millions of Americans to undertake jaunts into the countryside ... little longer within a century, according to new research. , ... of the United States as summer temperatures linger later into ... Global Ecology and Biogeography . For instance, the paper birch ... of New Hampshire could change color one to three ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... has won a $1.175 million grant that will support its ... Geurts, who has spent his career looking for clues to ... contents of gold, lead and other heavy atoms, said the ... constructing and commissioning a highly complex detector system to using ...
... that sheds new light on the causes of Parkinson,s disease, ... energy-producing machinery, the mitochondria. A shutdown in fuel can have ... of the body,s energy despite making up only 2 percent ... the mitochondria with FDA approved drugs early on may prevent ...
... billion last year in health research from all public ... That amount represents only 5.6% of the $2.47 trillion ... health dollarwhich varies no more than 0.2% from 2005 ... http://www.researchamerica.org/uploads/healthdollar09.pdf . The 2009 investment grew by ...
Cached Biology News:Grant advances quark-gluon plasma studies
 2Grant advances quark-gluon plasma studies
 3In Parkinson's disease, brain cells abandon mitochondria, researchers report 2In Parkinson's disease, brain cells abandon mitochondria, researchers report 3US invested $139 billion in health research in 2009 2
Roll of Mesh 5m x 25cm...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... (PPase-2A) is a serine/threonine phosphatase isolated from ... as the heterodimer of 60kDa (A) and ... to dephosphorylate the a-subunit of phosphorylase kinase. ... broad substrate specificity and may play a ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: